Targeted therapies have transformed treatment of driver-mutated metastatic NSCLC. We compared cardiovascular adverse events between and within targeted therapy classes. READ ARTICLE
Journal of Thoracic Oncology
DOI:10.1016/j.jtho.2021.07.030
Authors: Sarah Waliany, Han Zhu, Heather Wakelee, Sukhmani K. Padda, Millie Das, Kavitha Ramchandran, Nathaniel J. Myall, Thomas Chen, MD, Ronald M. Witteles, Joel W. Neal
Anaplastic Lymphoma Kinase (ALK) inhibitors have revolutionized the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC), improving progression-free survival. Bradycardia is a potential adverse effect of these agents. We aimed to determine the risk of bradycardia associated with ALK inhibitors in patients with advanced NSCLC.We find that crizotinib for the treatment of NSCLC is associated with a higher risk for bradycardia compared to standard chemotherapy. There is no evidence of a difference in bradycardia risk between crizotinib and newer ALK inhibitors. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2021.08.014
Authors: Filipe Cirne, Shijie Zhou, Coralea Kappel, Adam El-Kadi, Carly C. Barron, Peter M. Ellis, Stephanie Sanger, Darryl P. Leong
